secwatch.observer — SEC 8-K summary
======================================

Issuer:     Krystal Biotech, Inc. (KRYS)
CIK:        0001711279
Form:       8-K
Filed at:   2024-12-18T23:59:59+00:00
Accession:  0001711279-24-000065
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Krystal Biotech reports 27% ORR and 73% DCR for inhaled KB707 in advanced NSCLC
-------------------------------------------------------------------------------

- ORR of 27% (3 partial responses) and DCR of 73% in 11 evaluable NSCLC patients as of Dec 6, 2024.
- Lung target lesion ORR 36% (3 partial, 1 complete response) and DCR 82%.
- Treatment-emergent AEs mild to moderate; no Grade 4/5 events; outpatient administration feasible.
- Protocol amended to add two combination cohorts (with anti-PD-1 ± chemo) for advanced NSCLC.
- Enrollment ongoing; detailed results to be presented at future scientific meetings.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711279/000171127924000065/0001711279-24-000065-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711279/000171127924000065/krys-20241218.htm
  HTML page:      https://secwatch.observer/filing/0001711279-24-000065

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer